Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients

BACKGROUND: Metastatic renal cell carcinoma (mRCC) prognostic models may be improved by incorporating treatment-induced toxicities. METHODS: In sunitinib-treated mRCC patients (N=770), baseline prognostic factors and treatment-induced toxicities (hypertension (systolic blood pressure ⩾140 mm Hg), ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Donskov, Frede, Michaelson, M Dror, Puzanov, Igor, Davis, Mellar P, Bjarnason, Georg A, Motzer, Robert J, Goldstein, David, Lin, Xun, Cohen, Darrel P, Wiltshire, Robin, Rini, Brian I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705883/
https://www.ncbi.nlm.nih.gov/pubmed/26492223
http://dx.doi.org/10.1038/bjc.2015.368

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705883/
https://www.ncbi.nlm.nih.gov/pubmed/26492223
http://dx.doi.org/10.1038/bjc.2015.368

Ejemplares similares